A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocol. by Greenan, C et al.
STUDY PROTOCOL Open Access
A randomised controlled trial of calcium
channel blockade (CCB) with Amlodipine
For the treatment oF subcortical ischaEmic
vasCular demenTia (AFFECT): study
protocol
Caroline Greenan1, Lynn Murphy1, Ly-Mee Yu10, Patrick G. Kehoe2, Elizabeth Coulthard2, Philip Bath3,
Robert Stewart4, Rob Jones5, Anne Corbett6, Alan Thomas7, Peter Connelly8, Frank Arrojo9, Rachel Canning9,
Sylvia Wallach9, Catherine Henderson11, Bernadette McGuinness12, Mike O’Sullivan13, Clive Holmes14,
Martin Knapp11, Clive Ballard15, Peter Passmore12* and AFFECT Investigators
Abstract
Background: Vascular dementia is the second most common cause of dementia affecting over seven million
people worldwide, yet there are no licensed treatments. There is an urgent need for a clinical trial in this patient
group. Subcortical ischaemic vascular dementia is the most common variant of vascular dementia. This randomised
trial will investigate whether use of calcium channel blockade with amlodipine, a commonly used agent, can
provide the first evidence-based pharmacological treatment for subcortical ischaemic vascular dementia.
Methods/Design: This is a randomised controlled trial of calcium channel blockade with Amlodipine For the
treatment oF subcortical ischaEmic vasCular demenTia (AFFECT) to test the hypothesis that treatment with
amlodipine can improve outcomes for these patients in a phase IIb, multi-centre, double-blind, placebo-controlled
randomised trial.
The primary outcome is the change from baseline to 12 months in the Vascular Dementia Assessment Scale
cognitive subscale (VADAS-cog). Secondary outcomes include cognitive function, executive function, clinical global
impression of change, change in blood pressure, quantitative evaluation of lesion accrual based on magnetic
resonance imaging (MRI), health-related quality of life, activities of daily living, non-cognitive dementia symptoms,
care-giver burden and care-giver health-related quality of life, cost-effectiveness and institutionalisation.
A total of 588 patients will be randomised in a 1:1 ratio to either amlodipine or placebo, recruited from sites across
the UK and enrolled in the trial for 104 weeks.
Discussion: There are no treatments licensed for vascular dementia. The most common subtype is subcortical
ischaemic vascular dementia (SIVD). This study is designed to investigate whether amlodipine can produce benefits
compared to placebo in established SIVD. It is estimated that the numbers of people with VaD and SIVD will
increase globally in the future and the results of this study should inform important treatment decisions.
Trial registration: Current Controlled Trials ISRCTN31208535. Registered on 7 March 2014.
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Background
Worldwide there are approximately 35.6 million people
with dementia and this is expected to rise significantly in
the next decade [1].Vascular dementia (VaD) is the second
most common cause of dementia (approximately 20 %)
accounting for over seven million people worldwide. It is
estimated that VaD affects 1–4 of every 100 individuals
aged 65 years [2] and the prevalence increases to 14–16 of
every 100 people over 80 years of age [3].
VaD can arise due to a number of different underlying
cerebrovascular pathologies that were defined accord-
ing to a consensus classification of Vascular Cognitive
Impairment developed by international experts under the
auspices of the International Psychogeriatric Association
[4]. VaD is very heterogeneous condition that has been a
major barrier to developing and evaluating effective
therapies.
Subcortical ischaemic vascular dementia (SIVD) is the
most common form of VaD and results from small-
vessel disease. This disease produces either cavitating le-
sions in white or subcortical grey matter called lacunes
and diffuse damage to white matter connections often
attributed to incomplete infarction due to critical sten-
osis of medullary arterioles and hypoperfusion. Symp-
toms include motor and cognitive slowing, difficulty
with complex tasks (executive dysfunction), problems
with memory retrieval, dysarthria, mood changes, urin-
ary symptoms, and short-stepped gait [5]. These mani-
festations probably result from ischaemic interruption of
parallel circuits from the prefrontal cortex to the basal
ganglia and corresponding thalamocortical connections.
Brain imaging [computed tomography (CT) and magnetic
resonance magnetic resonance imaging (MRI)] has been
instrumental in revealing the prevalence of subcortical
lesions, rejuvenating the concept of SIVD, and provides a
ready means to identify subcortical vascular disease, which
is needed to reach a diagnosis of SIVD in practice.
SIVD is a priority candidate for development and
evaluation of effective treatments for VaD for a number
of reasons. First, SIVD is the most common form of
VaD and there is a need to focus on people with more
homogeneous forms of VaD to effectively develop and
evaluate new therapies that could realistically be imple-
mented in clinical practice. In addition, the strong age-
correlated prevalence of subcortical lesions combined
with an ageing population means that the prevalence of
SIVD is increasing. Alongside the age-related rise in sub-
cortical pathology, the relative contribution of SIVD to
vascular dementia is rising. Furthermore, progress in the
treatment of large-vessel vascular disease has unfortu-
nately not been accompanied by improvements in treat-
ment of small-vessel disease, including SIVD [6].
A Cochrane review identified 15 studies examining the
benefit conferred by calcium channel blockers (CCBs) in
dementia, including Alzheimer’s disease (AD), VaD and
non-specific dementia types. Of these studies ten specif-
ically examined VaD [7], the majority of which were very
small and did not use operationalised diagnostic criteria
to recruit participants. However, the review highlighted
three studies that involved more than 50 people with
VaD according to operationalised criteria. Of these, two
studies of 12 weeks duration included 67 and 62 partici-
pants respectively, and showed benefits in cognitive
function and global clinical outcome [8, 9]. The largest
reported study, which included 259 people over 6 months
found no significant benefit in cognitive outcomes in the
overall study population of people with VaD [10]. How-
ever, a post hoc subgroup analysis of 92 people with
SIVD from this study showed significant improvement
in both cognitive and functional outcome measures,
contrary to the lack of effect seen in a subgroup of
people with multi-infarct dementia. The authors
highlighted the need for a larger a priori trial of CCBs
specifically in people with SIVD [10].
Study rationale
VaD is a highly significant health issue, affecting millions
of people worldwide. This condition presents a substan-
tial challenge and burden for health service provision,
health economics and both informal and formal care.
Despite this there are no effective pharmacological treat-
ments. Developing new, effective treatments is therefore
an urgent imperative to ensure this enormous unmet
need is addressed.
SIVD is a progressive condition with many patients
showing hypertension and hypercholesterolaemia, in
addition to other cardiovascular comorbidities. Some
studies have been conducted and further ongoing studies
are evaluating the prevention of post-stroke dementia.
However, to date, AFFECT is the only registered
pharmacological treatment trial for SIVD.
CCBs have a consistent effect on stroke reduction
[11–14], can alter calcium flux in a beneficial way in
neurons [15] and have been shown to improve memory
in hypertensive patients [16]. The previous studies in
VaD and in SIVD in particular, strongly suggest the need
for a properly designed randomised clinical trial to in-
vestigate CCBs in SIVD.
Amlodipine is a commonly used CCB that is now
available generically at doses of 5 mg and 10 mg. It is
usually initiated at the 5 mg daily dose and titrated to
10 mg. In this study, the maximum tolerated dose will
be used, as this is most likely to demonstrate an effect
without the compromise of side effects.
Methods/Design
The Belfast Health and Social Care Trust (BHSCT) is
the Sponsor for this trial that will be conducted in
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accordance with the ethical principles that have their
origin in the Declaration of Helsinki. The protocol was
approved by the Office for Research Ethics Committees,
Northern Ireland (14/NI/0069). The trial is registered on
the International Standard Randomized Controlled Trial
Registry (ISRCTN31208535ISRCTN31208535) and with
the European Union Drug Regulating Authorities
Clinical Trials database (2014-000926-39). The study is
funded jointly by the Alzheimer’s Society and British
Heart Foundation and is being coordinated by the
Northern Ireland Clinical Trials Unit (NICTU) (http://
www.nictu.hscni.net). The trial will comply with the
principles of good clinical practice (GCP) and will be car-
ried out in accordance with applicable legislation and the
standard operating procedures of the NICTU. The trial
will be reported in line with the Consolidated Standards of
Reporting Trials (CONSORT) 2010 guidelines.
Study design
The AFFECT trial is a multi-centre, randomised,
double-blind, placebo-controlled, parallel phase IIb trial
of amlodipine in patients with SIVD.
Patients with SIVD fulfilling the eligibility criteria will
be randomised in a 1:1 ratio to either amlodipine or
matching placebo: 5 mg once daily for 2 weeks followed
by 10 mg once daily for 50 weeks. A total of 588 patients
aged above 50 years from a community setting will be
recruited from sites across the UK. Patients will be en-
rolled in the study for 104 weeks; 52 weeks on treatment
and a follow-up telephone call at 104 weeks. Patients
will attend the clinic for seven visits throughout the
study at screening, baseline, 6, 13, 26, 39, 52 weeks as
outlined in Fig. 1.
Outcome measures
The primary outcome measure will be a change from
baseline to 12 months in Vascular Dementia Assessment
Scale cognitive subscale (VADAS-cog) score. The
VADAS-cog is a more detailed cognitive assessment
designed to be more sensitive than the Alzheimer’s
Disease Assessment Scale-Cognitive subscale (ADAS-
Cog) to the cognitive outcomes in people with vascular
dementia [17]. This assessment should be completed face
to face by an assessor who will be blinded to the
intervention.
There are a number of secondary outcomes for this
trial that include:
 Change in cognitive function measured with the
standardised Mini-Mental State Examination
(sMMSE) from baseline to 12 months [18].
 Change in the Trail Making test B [19] from baseline
to 12 months. The Trail Making test B is a timed
measure of executive function.
 Change in cognitive function from baseline to
12 months measured by Modified Telephone
Interview for Cognitive Status [20]. There will also
be a follow-up at 24 months.
 Change in Clinical Global Impression of Change
(CGIC) [21] from baseline to 12 months. CGIC is a
simple standardised rating of overall clinical
outcome, rated by a clinician blind to treatment
allocation.
 Change in blood pressure from baseline to 12 months.
 Change in lesion accrual from baseline to 12 months.
This will be based on quantitation of lacunar
lesions and diffuse white matter lesions measured
quantitatively by MRI.
 Change in patient-reported health-related quality of
life from baseline to 12 months measured with the
EuroQol Group EQ-5D Health Questionnaire
(EQ-5D) [22] and the Dementia Quality of Life-
Proxy [23], a carer-rated and disease-specific
measure of quality of life in dementia.
 Change in activities of daily living (ADL) from
baseline to 12 months measured using the Disability
Assessment in Dementia [24].
 Change in non-cognitive dementia symptoms
from baseline to 12 months measured with the
Neuropsychiatric Inventory Caregiver Distress [25].
 Change in caregiver burden from baseline to
12 months measured with the 12-item General
Health Questionnaire [26], and care-giver health-
related quality of life measured with the EQ-5D-5
level (5L).
 Cost-effectiveness measured as the combination of
costs generated from the Client Service Receipt
Inventory [27] and effectiveness measured by
VADAS-cog, quality-adjusted life-years (QALYs)
from DEMQOL-Proxy and EQ-5D-5L.
 Institutionalisation defined as permanent transition
from living in an independent household to a care
home, nursing home, National Health Service
(NHS) continuing care unit or hospital and
measured with questions taken from the client
service receipt inventory (CSRI).
Eligibility criteria
Patients will be eligible to participate in the study if they
fulfil all of the following inclusion criteria:
1. Dementia syndrome according to the criteria a, b
and d from code 290.4 of the Diagnostic and
Statistical Manual of Mental Disorders, Fourth
Edition (DSM-IV) [28].
2. Evidence of one or more clinical features in support
of SIVD such as executive dysfunction, mood or gait
disturbance or focal neurological signs [29]. Patients
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Fig. 1 Study schematic for the AFFECT trial
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who present solely with low mood and a small
number of lacunar lesions will only be included if
there are additional indicators from other domains
(e.g. gait, neurological signs, executive dysfunction).
3. Multiple lacunae (>2) or diffuse lesions reaching a
mean Fazekas score of 2–3 across brain regions
identified on baseline MRI scan.
4. sMMSE score between 15 and 26 (inclusive).
5. Age ≥ 50
6. Evidence of adequate intellectual functioning so that
patient is capable of giving consent.
7. In patients taking a cholinesterase inhibitor or
memantine, dose stable for at least 3 months. All
subjects taking cholinesterase inhibitors or
memantine will have to be vetted for inclusion by
the Diagnostic Monitoring and Event Adjudication
(DMEA) Committee to ensure that the primary
diagnosis is not AD.
8. In patients taking antidepressants, dose stable for at
least 4 weeks.
9. CT or MRI scan consistent with the probable
diagnosis of SIVD providing there has been no
significant clinical change since the scan.
10.Patient has resident family or professional carer or is
visited at least twice a week by carer.
11.Fluency in English is essential as the study requires
questionnaires to be completed.
12.Likely to be able to participate in all scheduled
evaluations and complete all required tests.
13.Provision of appropriate consent.
14.Presence of an informant, aged 18 years or over who
is willing to participate in the study.
Patients fulfilling any of the criteria below will be ex-
cluded from the trial:
1. Severe, unstable or poorly controlled medical
conditions apparent from physical examination or
clinical history.
2. Moderate/severe heart disease or severe hepatic
disease.
3. Significant renal insufficiency; estimated glomerular
filtration rate (eGFR) <30 ml/min.
4. Blood pressure (sitting) exceeds 160 mmHg systolic
and/or 110 mmHg diastolic.
5. Systolic blood pressure (sitting) is less than
110 mmHg.
6. Infarction involving the cortex on MRI scans.
7. Cerebrovascular event within the last 6 months.
8. Myocardial infarction within the last 3 months.
9. Already taking any calcium channel blocker.
10.Contraindications to a calcium channel blocker as
per summary of product characteristics (SPC).
11.Patient is unable to take trial medications.
12.Pregnant women, women who have not yet reached
the menopause (no menses for ≥12 months without
an alternative medical cause) who test positive for
pregnancy, are unwilling to take a pregnancy test
prior to trial entry or are unwilling to undertake
adequate precautions to prevent pregnancy for the
duration of the trial.
13.Female patients who are breastfeeding.
14.AD is considered to be the primary diagnosis,
i.e. a predominantly amnestic presentation or
evidence of an amnestic (pre-dementia) phase or
strong biomarker evidence to support a diagnosis
of AD. Patients with severe hippocampal atrophy on
MRI (Scheltens GR 3 and 4 on both sides [i.e. a total
score (left plus right) of 6 or more will be excluded].
15.Significant neurological disease that may affect
cognition other than SIVD or AD as a concurrent
pathology.
16.Current presence of a clinically significant major
psychiatric disorder (e.g. Major Depressive Disorder)
according to the criteria of the DSM-IV.
17.Current clinically significant systemic illness that is
likely to result in deterioration of the patient’s
condition or affect the patient’s ability to complete
the study or their safety during the study.
18.Treatment with immunosuppressive medications
(e.g. systemic corticosteroids) within the last
90 days (topical and nasal corticosteroids and
inhaled corticosteroids for asthma are permitted)
or chemotherapeutic agents for malignancy within
the last 3 years.
19.Other clinically significant abnormality on physical,
neurological, laboratory, examination that could
compromise the study or be significantly detrimental
to the patient (e.g. postural hypotension diagnosed
within the last year which in the opinion of the
Principal Investigator (PI) would exclude the
patient).
20.Alcohol or drug dependence or abuse within the last
2 years.
21.Treated with any other investigational medication or
device within 60 days.
22.Patient taking simvastatin 40 mg or greater. A
patient may be switched to an alternative statin and
on stable dose for 3 months to meet the inclusion
criteria. A reduction in simvastatin dose solely for
the purposes of eligibility is not permitted.
Trial conduct
Withdrawal of consent
Patients may withdraw from the trial at any time without
prejudice. Permission will be sought for members of the
study team to access medical records for data related to
the trial. Data recorded up to the point of withdrawal
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will be included in the analysis, unless consent to use
their data has also been withdrawn.
Informants may withdraw from the trial at any time.
An attempt will be made to recruit an alternative in-
formant for the patient and consent obtained. However,
if this is not possible the patient will continue to be
followed up as part of the trial, unless the patient also
withdraws from the trial.
If the patient and/or informant requests termination
of the trial drug during the treatment period, the drug
will be stopped but the patient will continue to be
followed up as part of the trial, unless the patient with-
draws from the trial.
Randomisation procedure
Patients will be randomised with an allocation ratio of
1:1 amlodipine to placebo using Sortition, an online
randomisation system developed by the Primary Care
Clinical Trials Unit (PC-CTU) at the University of
Oxford.
A non-deterministic minimisation algorithm will be
used to ensure balanced allocation of patients across the
two treatment groups for the following important prog-
nostic factors: vascular risk score, smoking status, age,
prescription of a cholinesterase inhibitor/memantine
and the use of statins at baseline.
The randomisation service will assign a unique trial
identifier to each patient and confirm the study drug
pack number to be dispensed by the local pharmacy.
The randomisation service will confirm randomisation
details by email to the site, local pharmacy and the
clinical trials unit (CTU).The unique trial identifier
assigned at the time of randomisation will be used
throughout the trial for the purposes of patient iden-
tification. The online randomisation system will also
confirm the study pack numbers to be dispensed at
visits 4, 5 and 6.
Unblinding procedure
As a double-blind placebo-controlled trial, patients, cli-
nicians and the PI will be blinded to each patient’s treat-
ment allocation. Patients will be given a Patient Study
Card when they are enrolled in the trial. This will in-
clude 24-hour contact details of their treating clinician
in the event that the patient needs to contact their clin-
ician. A standardised procedure for emergency unblind-
ing will be available to all participating sites.
Emergency unblinding may be requested on safety
grounds, or if the treatment decision for a patient
could be influenced by the knowledge of what the pa-
tient is taking as part of the trial. If the PI or desig-
nated Investigator decides that there is justification to
unblind a patient, emergency unblinding will be per-
formed via the online randomisation service. In the
event unblinding occurs, the patient may discontinue
study drug but will remain on the trial unless they
decide to withdraw.
Study treatment regimen
Patients will be randomised to (1) usual care + amlodipine
or (2) usual care +matching placebo.
The usual care for patients will include written infor-
mation about risk reduction in vascular dementia. This
will be based on the most up-to-date evidence and ad-
vice. They will then continue to receive the usual care
provided by their general practitioner (GP).
Patients will receive 5 mg amlodipine daily or match-
ing placebo for 2 weeks, increasing to 10 mg daily of
amlodipine or matching placebo for 50 weeks. The dose
will be reduced back to 5 mg or matching placebo daily
if intolerable side effects develop. If the dose is reduced
to 5 mg there will be no further increase to 10 mg for
the remainder of the trial.
Patients should commence study medication (5 mg)
the day after the baseline visit and for all subsequent
visits patients should take their study medication before
attending the visit. Study medication should be adminis-
tered in the morning. If the study medication is not
taken in the morning it can be administered up to
12 hours later. Two doses should not be taken at once.
Study drug supply
Study drug packs will be packaged and labelled by
Victoria Pharmaceuticals (Belfast, UK). Amlodipine
5 mg or placebo will be packaged in containers of 210
tablets and labelled in compliance with the applicable
regulatory requirements.
Hospital pharmacies will maintain accurate records of
all Investigational Medicinal Product (IMP) received
(including date of receipt, batch numbers, expiry date,
quantities of drug shipments), dispensed and returned
on the Drug Accountability Log. Hospital pharmacies
will ensure all study drugs are stored in a secured area
under the manufacturer’s recommended storage condi-
tions and held separately from normal hospital stock.
Study drug compliance
Patients will be asked to store the medication according
to the manufacturer’s instructions and should bring all
unused medication and empty bottles to each visit.
Research staff will perform a count and return any
unused medication and empty bottles to the site
pharmacy. Patients who have taken 80 % or more of
the expected number of tablets will be considered
compliant. Non-compliance should be discussed with
the PI or designee to determine if appropriate to dis-
continue medication but continue patient follow up
as part of the trial.
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Study drug termination criteria
Prior to the maximum treatment period of 52 weeks
(1 year after randomisation), study drug will be discon-
tinued if any of the following conditions are met:
– Patient or informant request termination of study
drug
– Patient or informant withdraws consent for the
study
– Non-compliance with study drug as determined by
the PI (patients who have taken 80 % or more of the
expected number of tablets will be considered
compliant)
– Side effects remain intolerable following the
reduction of the study drug to 5 mg
– Decision by the PI that the study drug should be
discontinued on safety grounds
The reason for study drug termination should be
recorded and any unused medication returned to
pharmacy.
Study assessments
All patients must be evaluated during the study accord-
ing to the schedule of assessments (+/- 7 days) outlined
in Table 1 and data recorded within the case report form
(CRF).
MRI assessments
MRI assessments will be completed prior to visit 2
(baseline) to confirm patient eligibility and at visit 7
(52 weeks) as part of the final outcome assessments.
Lacunar lesions will be identified and distinguished from
mimics such as enlarged perivascular spaces, based on
existing criteria. Diffuse white matter abnormalities will
be evaluated according to the age-related white matter
changes (ARWMC) radiological scale and validated
across imaging modalities [30]. The scale grades white
matter lesions into punctate, early confluent and conflu-
ent, a rating system which has been validated against
pathology based on the Fazekas criteria [31]. Lacunar in-
farcts definitions are based on the STRIVE criteria by
Wardlaw et al. [32].
Review of the MRI images will be completed centrally
at the AFFECT Imaging Co-ordinating Centre (ICC)
overseen by a central team consisting of neurology ex-
perts. The central evaluation will be based on a validated
scale as reported by Barkhof [33]. During the study a
subset of images and screening results will also be pro-
vided to the DMEA Committee for the purposes of
oversight.
Only once the MRI results are known and all base-
line assessments are completed confirming eligibility,
should the patient be randomised to the study. Ideally,
randomisation should occur within 4 weeks (+/- 7 days)
of the screening visit. Patients will be contacted prior to
their 52-week visit to schedule the final MRI assessment.
Current medications
Current medication details will be recorded for each pa-
tient at every visit.
If patients are taking cholinesterase inhibitors or mem-
antine, the dose needs to be stable for at least 3 months
prior to commencing the study drug. The DMEA
Committee will assess patients taking cholinesterase in-
hibitors or memantine for inclusion in the study.
Cognitive assessments
All cognitive assessments should be completed face to
face by an assessor who will be blinded to the interven-
tion as outlined in Table 1.
At visit 2 (baseline), the cognitive assessments should
take place on the same day as the patient is randomised
to the study. At visit 7 (52 weeks), the cognitive assess-
ments may take place on the same day as the MRI or
pre/post the MRI. Both the MRI and cognitive assess-
ment should be completed within -/+ 7 days of the 52-
week visit date. The TICS-M questionnaire is a tele-
phone questionnaire and should be completed the week
of the baseline visit but prior to the patient starting the
study medication the day after the baseline visit. A
telephone follow-up call should also be completed on
the week of visits 26, 52 and 104 weeks to complete
the modified telephone interview for cognitive status
(TICS-M) questionnaire.
Service use and costs questionnaire
The CSRI will be completed by an assessor in a face-to-
face interview with the informant. In addition, a log will
be provided to patients at the end of visits 2, 4, and 6.
The log is to be used as an optional memory aid to help
patients recall service use in the period prior to each as-
sessment point [34].
Biochemistry profile and full blood count
A blood sample should be taken at visits 1, 2, 5 and 7
and a biochemistry profile and full blood count will be
carried out.
Vital signs
At each visit the patient’s weight, heart rate, sitting (after
10 minutes, second reading) and standing blood pres-
sure (1 minute) should be measured and recorded on
the CRF.
An electrocardiogram (ECG) should be carried out at
visits 1, 2, 5 and 7. The PI or designee should review
and sign off the ECG stating if the results present
any non-clinically significant or clinically significant
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abnormalities. The PI or designee should detail all
clinically significant abnormalities.
Clinical management of patients on the trial
Four weeks following the commencement of patients on
study medication (i.e. 2 weeks at 5 mg once daily dose
followed by 2 weeks at 10 mg once daily dose), a
telephone follow-up call should be completed by each
participating site to assess if the patient is experiencing
any side effects. It should also be confirmed if the pa-
tient has increased the dose of study medication to
10 mg daily. The most common side effects include
headache, oedema, flushing, dizziness, ankle swelling,
fatigue, nausea, and rash. If the patient reports any
Table 1 Schedule of assessments
Visit 1 2 3 4 5 6 7
Assessment Screening Baseline Week 2 Week 4 Week 6 Week 13 Week 26 Week 39 Week 52 Week 104
Informed consent x
Inclusion and exclusion criteria review x x
Patient demographics x
Vital signs x x x x x x x
Informant demographics x
Patient clinical and medical history x
Physical examination x x x
Neurological assessment x x x
Previous medications x
Current medications x x x x x x x
Co-morbidities x
Biochemistry profile x x x x
Full blood count x x x x
ECG x x x x
MRI x x
Telephone follow-up x x
Cognitive assessments
VADAS-cog x x x x x x
CGIC x x x x
sMMSE x x x x x
Trail Making B x x x x
TICS-M x x x x
Informant/Patient Questionnaires
EQ-5D x x x x
DAD (informant) x x x x
GHQ12 (informant) x x x x
EQ-5D (informant) x x x x
DEMQOL (informant) x x x x
NPI-D (informant) x x x x
CSRI (informant) x x x x
Service use log x x x
Advice sheet x
Adverse events x x x x x x x
Study drug dispensing x x x x
ECG electrocardiograph, MRI magnetic resonance imaging, VADAS-cog vascular dementia assessment scale cognitive subscale, CGIC clinical global impression of
change, sMMSE standardised Mini-Mental State Examination, TIC-M modified telephone interview for cognitive status, EQ-5D EuroQol group 5 dimensions health
questionnaire, DAD disability assessment in dementia, GHQ12 12-item general health questionnaire, DEMQOL dementia quality of life, NPI-D neuropsychiatric
inventory caregiver distress, CSRI client service receipt inventory
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intolerable side effects, the PI should be notified who
will monitor the patient and decide on the action to be
taken.
If there is significant postural hypotension (drop in
systolic blood pressure on standing of greater than
20 mmHg), and the patient is taking 10 mg study
medication, the dose should be reduced to 5 mg daily.
However, if significant postural hypotension persists fol-
lowing the decrease of study medication to 5 mg, the pa-
tient will be re-assessed by the PI who will decide
whether the study drug is to be stopped.
If the patient’s blood pressure is found to be greater
than 160 mmHg systolic or 100 mmHg diastolic, then
the patient’s GP should be advised to monitor the pa-
tient’s blood pressure to determine if it remains elevated
to this level. If the patient’s blood pressure remains ele-
vated, then antihypertensive medication will need to be
prescribed. The GP should be advised that any antihy-
pertensive medication, except a CCB can be prescribed.
Data collection
To ensure accurate, complete and reliable data are col-
lected, training will be provided to site staff in the for-
mat of investigator meetings and/or site initiation visits.
All data for an individual patient/informant will be
collected by each PI or their delegated nominees and
recorded in the electronic database/source document.
Patient/informant identification will be through their
unique trial identifier allocated at the time of randomisa-
tion and initials. Data will be collected and recorded on
the CRF and questionnaires by the site research team
from the time the patient and their informant are con-
sidered for entry into the trial through to their 104-week
telephone follow up.
Adverse events
The PI will record all directly observed adverse events
(AEs) and all AEs spontaneously reported by the
patient/informant. In addition, the patient/informant will
be asked about AEs at each visit following initiation of
treatment.
Events associated with the patient’s underlying medical
condition should not be reported as AEs. AEs of special
interest that should be reported include dizziness and
falls. All adverse reactions (ARs), an AE which is related
to the administration of the study drug must be reported
on the AE form within the CRF. An unexpected adverse
reaction (UAR) is an AE which is related to the adminis-
tration of the study drug and that is unexpected, in that
it has not been previously reported in the current SPC.
All UARs must be reported on the AE form within the
CRF.
All serious adverse events (SAEs), SAEs that are re-
lated to the administration of the study drug (SARs)
and suspected unexpected serious adverse reactions
(SUSARs) will be reported to the CTU within 24 hours of
becoming aware of their occurrence. The CTU will inform
the Sponsor and regulatory authorities within the required
timelines as per the regulatory requirements.
Sample size
Based on results obtained from the CADASIL study
[35], a minimum total sample size of 470 patients will
need to be recruited to achieve a small but clinically
meaningful standardised effect size of 0.3. Thus 588 pa-
tients overall (i.e. 294 patients per treatment group) will
be recruited. This is based on a standard deviation of
8.4, and assuming a dropout rate of 20 %, at 90 % power
and 5 % level of significance (two-sided).
Data analysis
The principal comparisons will be performed on an
intention-to-treat (ITT) basis. Thus, after randomisation,
patients will be analysed according to their allocated
treatment group irrespective of what treatment they ac-
tually receive. Full follow-up data will be obtained on
every patient to allow full ITT analysis, however missing
data will be problematic due to withdrawal, loss to
follow-up, or non-response response questionnaire
items. The results from the trial will be presented as
comparative summary statistics (difference in response
rates or means) with 95 % confidence intervals. The
study results will be reported in accordance with the
Consolidated Standards of Reporting Trials (CONSORT)
2010 statements [36]. A fully detailed statistical analysis
plan (including plans for any interim analysis, subgroup
analysis, and sensitivity analysis) will be prepared be-
fore the first interim analysis. The report to the Data
Monitoring and Ethics Committee (DMEC) will be
prepared approximately 6 months after recruitment
has started.
Primary outcome (VADAS-cog) will be analysed using
linear mixed-effects models, with repeated measures on
outcome measurements at weeks 6, 13, 26, 39 and
52 weeks, adjusting for baseline score, stratification and
minimisation variables. Falls will be specifically evaluated
as an adverse event of special interest as part of the
safety comparison. An interaction between time and ran-
domised group will be fitted to allow estimation of treat-
ment effect at each time point. The distribution of the
change from baseline will be formally assessed for evi-
dence of departure from normality. If necessary, data
will either be transformed or analysed using a non-
parametric equivalent.
The nature and mechanism for the missing outcomes
will be investigated, though mixed-effects models impli-
citly account for data missing at random mechanism.
Pre-specified subgroup analysis such as use of statins at
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baseline will be explored. Sensitivity analyses will be car-
ried out to examine the robustness of the results with
different assumptions about departures from randomisa-
tion policies, and handling of missing data.
For secondary outcomes, the distributions of the
changes in the continuous secondary outcome measures
will be formally assessed for evidence of departure from
normality. In instances where such changes in outcome
are not normally distributed, data will be either trans-
formed and analysed as detailed above or tested using
non-parametric equivalents.
The 52-week study data will be published following
the collation and analyses of this data set. The 104-week
TICS-M data will be published thereafter. The 104-week
TICS-M assessment will be an important long-term out-
come with valuable information examining the outcomes
for patients with SIVD.
Stopping guidelines
In the light of the DMEC report and other evidence
from relevant studies, the DMEC will inform the Trial
Steering Committee (TSC) if, in its view, there is proof
beyond reasonable doubt that the data indicate the trial
should be terminated. It is agreed that recommendations
on premature stopping of the trial are more likely to be
made on the grounds of safety as there will be no in-
terim analysis carried out for the primary outcome of ef-
fectiveness. Therefore, any interim analysis related to the
effectiveness of the study will be included in the DMEC
report as guidance for benefit-to-risk assessment.
Economic analysis
Service utilisation patterns, carer inputs and all associ-
ated costs will be calculated for each patient, based on
data collected from study drug logs and a modified ver-
sion of the CSRI completed by the informant at baseline,
13, 26 and 52 weeks. Unit costs to reflect long-run mar-
ginal opportunity costs will be attached using national
figures where available, or calculated anew if necessary.
Cost-effectiveness analyses (CEAs) will be conducted
to compare effectiveness and costs over the 52-week
period, each from the perspective of (a) the NHS and so-
cial services, and (b) society as a whole (including un-
paid carer costs).
The primary outcome measure will be the incremental
cost of a change in VADAS-cog score from baseline to
12-month follow-up. The secondary outcome measures
will be the incremental cost of quality-adjusted life-years
(QALY) gained, using utility scores calculated from the
DEMQOL-Proxy [37] and from the EQ-5D-5 L with
societal weights [38]. Further CEAs will be conducted
for other key outcomes: CGIC, sMMSE, DAD, NPI-D,
and TICS-M. Cost-effectiveness ratios will be compared
with other studies of dementia treatment and (where
appropriate) of other treatments, and with National
Institute for Health and Clinical Excellence (NICE)
thresholds when using QALYs as the effectiveness
measure.
Cost comparisons will be made between intervention
and control groups, with adjustments probably needed
to adjust for non-normality of data (using bootstrap
methods or generalized linear modelling). For each hy-
pothesis, relevant perspective and outcome, an incre-
mental cost-effectiveness ratio will be computed and
compared with results from other studies where appro-
priate. Cost-effectiveness acceptability curves will be
plotted using bootstrap analyses to address uncertainty
and locate the findings of the economic evaluation in
their wider decision-making context.
Trial oversight
The Chief Investigator (CI) will have overall responsibil-
ity for the conduct of the study. The Trial Management
Group (TMG) will have responsibility for the day-to-day
operational management of the trial. The conduct of the
trial will be overseen by a Trial Steering Committee
(TSC). The TSC comprising investigators, clinicians, tri-
alists and lay members act as the oversight body for the
trial on behalf of the Sponsor/Funder. Throughout the
trial, the TSC will take responsibility for monitoring and
guiding overall progress, scientific standards, operational
delivery and protecting the rights and safety of trial pa-
tients. An independent Data Monitoring and Ethics
Committee (DMEC) will be appointed with responsibil-
ity for safeguarding the interests of trial patients, they
will monitor the main outcome measures including
safety and efficacy and assist and advise the TSC so as to
protect the validity and credibility of the trial. A
Diagnostic Monitoring and Events Adjudication (DMEA)
Committee will also be established to evaluate protocol
compliance, safeguard diagnostic accuracy and ensure the
inclusion/exclusion criteria are met. This includes a review
of MRI scans for patients on cholinesterase inhibitors or
memantine and patients who experience disabling stroke/
vascular events. In addition, the DMEA Committee will
also review a number of randomly selected MRI scans.
Discussion
Vascular dementia is a very common cause of dementia
syndromes. There are no treatments licensed for VaD
and there is an urgent need for intervention studies in
this condition. It is a heterogeneous condition and the
most common subtype is subcortical ischaemic vascular
dementia. This study is designed to investigate SIVD in
order to maintain a homogeneity within the study group.
The agent chosen for intervention is amlodipine, a dihy-
dropyridine calcium channel blocker. There is back-
ground information that calcium channel blocking drugs
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can have useful effects in people with SIVD but that
there is a need for improved studies in the area of VaD
and SIVD . Amlodipine is a very commonly used agent
in this class which has been available for many years for
the treatment of hypertension. This study is designed to
investigate whether amlodipine can produce benefits
compared to placebo in established SIVD. The design of
the study, with multiple centres, a double-blind placebo
controlled protocol, and central randomization, maxi-
mises recruitment opportunities and minimises the risk
of selection or allocation bias. It is estimated that the
numbers of people with VaD and SIVD will increase glo-
bally in the future and the results of this study should
inform important treatment decisions.
Trial status
Recruitment is ongoing.
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